SEGMENT INFORMATION TECHNE CORPORATION AND SUBISIDARIES (in thousands of $'s, except per share data) Increase (Decrease) Fiscal 2009 From Fiscal 2008 ----------------- ---------------- First Percent First Quarter of Sales Quarter ------- -------- ------- Sales 69,324 100% 11,337 Cost of sales 13,086 19% 982 ------- -------- ------- Gross margin 56,238 81% 10,355 Gross margin percentage 81.1% SG&A expense 8,840 13% 750 R&D expense 5,910 8% 729 Amortization expense 240 -- (48) Interest income (2,887) (4%) 111 Other non-operating ex., net 1,187 2% 618 ------- -------- ------- 13,290 19% 2,160 ------- -------- ------- Earnings before income taxes 42,948 62% 8,195 Income taxes 14,355 21% 2,674 ------- -------- ------- 28,593 41% 5,521 ======= ======== ======= Diluted earnings per share 0.74 Weighted average diluted shares outstanding 38,747 BIOTECHNOLOGY (1) (in thousands of $'s) Increase (Decrease) Fiscal 2009 From Fiscal 2008 ----------------- ---------------- First Percent First Quarter of Sales Quarter ------- -------- ------- Sales 53,899 100% 8,571 Intersegment sales (7,762) (1,315) ------- ------- 46,137 7,256 Cost of sales 10,247 19% 1,250 Intersegment sales (7,461) (1,287) ------- ------- 2,786 (37) ------- -------- ------- Gross margin 43,351 81% 7,293 Gross margin percentage 81.0% SG&A expense 5,141 10% 517 R&D expense 5,717 11% 715 Amortization expense 240 -- (48) Interest, net (1,084) (2%) 173 Exchange loss/(gain) (2) -- (36) ------- -------- ------- 10,012 19% 1,321 ------- -------- ------- Pretax result 33,339 62% 5,972 ======= ======== ======= (1) Includes R&D Systems' Biotechnology Division, BiosPacific, Inc. and R&D China R&D SYSTEMS EUROPE (in thousands of British pounds) Increase (Decrease) Fiscal 2009 From Fiscal 2008 ----------------- ---------------- First Percent First Quarter of Sales Quarter ------- -------- ------- Sales 10,175 100% 2,570 Cost of sales 4,260 42% 805 ------- -------- ------- Gross margin 5,915 58% 1,765 Gross margin percentage 58.1% SG&A expense 1,224 12% 110 Interest income (790) (8%) (107) Exchange loss/(gain) 260 3% 356 ------- -------- ------- 694 7% 359 ------- -------- ------- Pretax result 5,221 51% 1,406 ======= ======== ======= R&D SYSTEMS EUROPE (in thousands of $'s) Increase (Decrease) Fiscal 2009 From Fiscal 2008 ----------------- ---------------- First Percent First Quarter of Sales Quarter ------- -------- ------- Sales 18,941 100% 3,492 Cost of sales 7,931 42% 911 ------- -------- ------- Gross margin 11,010 58% 2,581 Gross margin percentage 58.1% SG&A expense 2,283 12% 21 Interest income (1,471) (8%) (84) Exchange loss 476 3% 674 ------- -------- ------- 1,288 7% 611 ------- -------- ------- Pretax result 9,722 51% 1,970 ======= ======== ======= HEMATOLOGY (in thousands of $'s) Increase (Decrease) Fiscal 2009 From Fiscal 2008 ----------------- ---------------- First Percent First Quarter of Sales Quarter ------- -------- ------- Sales 4,246 100% 589 Cost of sales 2,369 56% 108 ------- -------- ------- Gross margin 1,877 44% 481 Gross margin percentage 44.2% SG&A expense 436 10% (31) R&D expense 193 4% 14 Interest, net (102) (2%) 18 ------- -------- ------- 527 12% 1 ------- -------- ------- Pretax result 1,350 32% 480 ======= ======== ======= CORPORATE AND OTHER (2) (in thousands of $'s) Increase (Decrease) Fiscal 2009 From Fiscal 2008 ----------- ---------------- First First Quarter Quarter ------- ------- Interest income 230 (4) Rental income 99 32 ------- ------- 329 28 SG&A expense 980 243 Other-Building expenses 553 9 Other-Equity Investment losses 259 3 ------- ------- 1,792 255 ------- ------- Pretax result (1,463) (227) ======= ======= (2) Unallocated corporate expenses and Techne's share of losses by Hemerus Medical, LLC and Nephromics, LLC.